ArticleTranslational vision science & technology2025
Visual Tract Integrity Before and After Gene Therapy in Congenital Achromatopsia.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: CNGA3 achromatopsia is a rare hereditary syndrome caused by dysfunction of cone photoreceptors. Visual information is therefore obtained only by rod photoreceptors, resulting in low acuity, photoaversion, and color blindness. Trials using gene therapy have been initiated recently, in which clinical improvement was subtle. Methods: To explain this suboptimal outcome, we used diffusion tensor imaging to assess visual pathway integrity in 3 CNGA3 achromatopsia patients before and after gene therapy, and compared them with 16 normally sighted adults. Results: No significant differences from normal subjects in optic tract and radiation were detected. Fiber integrity reduction was observed in the occipitocallosal fibers. These differences showed some normalization after treatment, but intersubject variability was evident. Specifically, the observed changes were related to radial diffusivities, reflecting fiber myelination or glial cell alterations. Conclusions: Despite the fundamental role of cone photoreceptors in human sight, primary visual pathways in patients are comparable with those of healthy individuals and thereby fiber integrity is probably not an obstacle for recovery. Preliminary results suggest that the splenial fibers are less cohesive in naïve patients and regain some integrity after treatment. These findings add to previous reports on this rare population and suggest that novel information is processed within the visual cortex after treatment. Translational Relevance: Patients with complete color blindness were treated using a novel gene augmentation therapy. Unfortunately, the patients did not experience a sudden eureka moment of being able to perceive the full spectrum of colors. In this study, we rule out fiber disintegration as the cause of their limited recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.